Publicacións en colaboración con investigadores/as de Complejo Asistencial Universitario de León (14)

2024

  1. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

2022

  1. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

2017

  1. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542

2014

  1. Breast cancer management in the elderly

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 351-361

2011

  1. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 686-691

  2. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

2010

  1. Novel therapeutic approaches to the treatment of metastatic breast cancer

    Cancer Treatment Reviews, Vol. 36, Núm. 1, pp. 33-42

2008

  1. Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer

    Clinical and Translational Oncology, Vol. 10, Núm. 11, pp. 739-744